


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

On July 5, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Lynda Ralovich



PATENT
Attorney Docket No.: 15270-001430US
Client Docket No.: 120-PCT-CIP1

COPY

TECH CENTER 1600/2900

APR 10 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mary M. Bendig et al.

Application No.: 09/155,739

Filed: September 11, 1998

For: THERAPEUTIC USES OF
HUMANIZED ANTIBODIES AGAINST
ALPHA-4 INTEGRIN

Examiner: Gambel, P.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. § 1.821(e)

RECEIVED

APR 06 2001

OFFICE OF PETITIONS

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed June 5, 2000, Applicants submit that the computer-readable form in the instant application is equivalent to the corrected sequence listing filed on August 25, 1994, in Application No. 08/186,269, filed January 25, 1994, Attorney Docket No. 015270-001400US.

In accordance with 37 C.F.R. § 1.821(e), please use the acceptable computer-readable form filed in Application No. 08/186,269 as the computer-readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that


will be used for the instant application. A paper copy of the sequence listing was included in the originally-filed specification of the instant application.

REMARKS

The information contained in the computer readable disk of Application No. 08/186,269 was prepared through the use of the software program "PatentIn" and was identical to that of the paper copy.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,


Andrew T. Serafini, Ph.D.
Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
ATS:nsc